The human sympathetic nervous system: Its relevance in hypertension and heart failure

European Heart Journal

Volumn 33, Issue 9, 2012, Pages 1058-1066

  Parati, Gianfranco ^a,b   Esler, Murray ^c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Arterial baroreflex; Arterial hypertension; Baroreceptor stimulation; Beta blockers; Catecholamines; Chronic heart failure; Microneurography; Renal denervation; Sympathetic activity

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BISOPROLOL; CARVEDILOL; CLONIDINE; GUANETHIDINE; METHYLDOPA; METOPROLOL; MOXONIDINE; NEBIVOLOL; NORADRENALIN; PROPRANOLOL; RILMENIDINE;

ADRENERGIC RECEPTOR BLOCKING DEVICE; ADRENERGIC SYSTEM; AEROBIC EXERCISE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CALORIC RESTRICTION; CAROTID SINUS PRESSORECEPTOR; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTROSTIMULATION; ESSENTIAL HYPERTENSION; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; IMPLANTABLE ARTERIAL BAROSTIMULATOR; INSULIN RESISTANCE; MICRONEUROGRAPHY; NEPHRECTOMY; NEUROGRAPHY; NEUROTRANSMITTER RELEASE; NORADRENALIN BLOOD LEVEL; NORADRENALIN URINE LEVEL; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; TAKOTSUBO CARDIOMYOPATHY;

ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM DISEASES; BAROREFLEX; BLOOD PRESSURE; CATHETER ABLATION; ELECTRIC STIMULATION THERAPY; EQUIPMENT DESIGN; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MYOCARDIUM; NOREPINEPHRINE; PROSTHESES AND IMPLANTS; RECEPTORS, ADRENERGIC, BETA; SLEEP APNEA, OBSTRUCTIVE;

EID: 84860609944     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs041     Document Type: Review

References (79)

1. Zimmer K. Soul Made Flesh. London: The Random House (Arrow Books); 2004. p188, 279.
2. Hamilton WF, Richards DW. Output of the heart. In: Fishman AP, Richards DW, eds. Circulation of the Blood. Men and Ideas. Bethesda: American Physiological Society; 1982, p87-90.
3. Cannon WB. Bodily Changes in Pain, Hunger, Fear and Rage. New York: D Appleton and Co, 1929.
4. Esler M. The 2009 Carl Ludwig Lecture. Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanism to medical management. J Appl Physiol 2010;108:227-237.
5. Von Euler US. A specific sympathetic ergone in adrenergic nerve fibres (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 1946;12:73-97.
6. Hagbarth K-E, Vallbo AB. Pulse and respiratory grouping of sympathetic impulses in human muscle nerves. Acta Physiol Scand 1968;74:96-106.
7. Engelman K, Portnoy B, LovenbergW. A sensitive and specific double isotope derivative method for the determination of catecholamines in biological specimens. Am J Med Sci 1968;255:259-268.
8. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3-20.
9. Friberg P, Meredith I, Jennings G, Lambert G, Fazio V, Esler M. Evidence of increased renal noradrenaline spillover rate during sodium restriction in man. Hypertension 1990;16:121-130.
10. Parati G, Mancia G, Di Rienzo M, Castiglioni P, Taylor JA, Studinger P. Point: counterpoint cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol 2006;101:676-682.
11. Macefield V, Wallin BG, Vallbo AB. The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves. J Physiol (Lond) 1994;481: 799-809.
12. Lambert E, Straznicky N, Schlaich MP, Dawood T, Hotchkin E, Esler MD, Lambert GW. Differing patterns of sympathoexcitation in normal weight and obesity-related hypertension. Hypertension 2007;50:862-868.
13. Hasking G, Esler M, Jennings G, Burton D, Johns J, Korner P. Norepinephrine spillover to plasma in congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621.
14. Parati G, Saul JP, Di Rienzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. Hypertension 1995;25:1276-1286.
15. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996;17: 354-381.
16. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991;84:482-492.
17. Bauer A, Malik M, Barthel P, Schneider R, Watanabe MA, Camm AJ, Schomig A, Schmidt G. Turbulence dynamics: an independent predictor of late mortality after acute myocardial infarction. Int J Cardiol 2006;107:42-47.
18. Voss A, Kurths J, Kleiner HJ, Witt A, Wessel N, Saparin P, Osterziel KJ, Schurath R, Dietz R. The application of methods of non-linear dynamics for the improved and predictive recognition of patients threatened by sudden cardiac death. Cardiovasc Res 1996;31:419-433.
19. Parati G, Di Rienzo M, Mancia G. How to measure baroreflex sensitivity: from the cardiovascular laboratory to daily life. J Hypertens 2000;18:7-19.
20. Parati G, di Rienzo M, Bertinieri G, Pomidossi G, Casadei R, Groppelli A, Pedotti A, Zanchetti A, Mancia G. Evaluation of the baroreceptor-heart rate reflex by 24-hour intra-arterial blood pressure monitoring in humans. Hypertension 1988;12:214-222.
21. Saul JP, Berger RD, Albrecht P, Stein SP, Chen MH, Cohen RJ. Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am J Physiol Heart Circ Physiol 1991;261:H1231-H1245.
22. Van de Borne P, Rahnama M, Mezzetti S, Montano N, Porta A, Degaute JP, Somers VK. Contrasting effects of phentolamine and nitroprusside on neural and cardiovascular variability. Am J Physiol Heart Circ Physiol 2001;281: H559-H565.
23. Julien C, Chapuis B, Cheng V, Barres C. Dynamic interactions between arterial pressure and sympathetic nerve activity: role of arterial baroreceptors. Am J Physiol Regul Integr Comp Physiol 2003;285:R834-R841.
24. Castiglioni P, Merati G, Veicsteinas A, Parati G, Di Rienzo M. Influence of sympathetic vascular regulation on heart-rate scaling structure: spinal cord lesion as a model of progressively impaired autonomic control. Biomed Tech 2006;51: 240-243.
25. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478-484.
26. Narkiewicz K, Winnicki M, Schroeder K, Phillips BG, Kato M, Cwalina E, Somers VK. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension 2002;39:168-172.
27. Pagani M, Somers V, Furlan R, Dell'Orto S, Conway J, Baselli G, Cerutti S, Sleight P, Malliani A. Changes in autonomic regulation induced by physical training in mild hypertension. Hypertension 1988;12:600-610.
28. Robbe HW, Mulder LJ, Ruddel H, Langewitz WA, Veldman JB, Mulder G. Assessment of baroreceptor reflex sensitivity by means of spectral analysis. Hypertension 1987;10:538-543.
29. Grassi M, Esler M. How to assess sympathetic activity in humans. J Hypertension 1999;17:719-734.
30. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 1965;39:442.
31. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005;26:906-913.
32. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962;267:650-654.
33. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-243.
34. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sagerman WS, Liuie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and b-adrenergic-receptor density in failing human hearts. New Engl J Med 1982;307:205-211.
35. Chidsey CA, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentration in man: effects of reserpine and of congestive heart failure. N Engl J Med 1963;269:653-658.
36. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-919.
37. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99: 2192-2217.
38. Cohn J, Levine T, Olivari MT, Garberg V, Tura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984;311:819-823.
39. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiology 1995;26:1257-1263.
40. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136-1143.
41. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77: 75-197.
42. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003;42:873-877.
43. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, Mancia G. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome. Characteristics and mechanisms. Hypertension 2007;49:535-541.
44. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F. Shortterm heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107:565-570.
45. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, Maron BJ, Page RL, Passman RS, Siscovick D, Stevenson WG, Zipes DP. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Circulation 2008;118: 1497-1518.
46. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80:7L-14L.
47. Packer M, Bristow MR, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
48. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
49. The Cardiac Insufficiency Bisoprolol Trial (CIBIS II). A randomized trial. Lancet 1999;353:9-13.
50. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJS, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009;53:2150-2158.
51. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW, BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1667.
52. Cohn JN, Pfeffer MA, Rouleau JR, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur Heart J 2003;5:659-667.
53. Smithwick RH, Bush RD, Kinsey D, Whitelaw GP. Hypertension and associated cardiovascular disease; comparison of male and female mortality rates and their influence on selection of therapy. J Am Med Assoc 1956;160:1023-1026.
54. Esler M. Looking at the sympathetic nervous system as a primary source. In: Zanchetti A, Robertson JIS, Birkenhager WH, eds, Handbook of Hypertension: Hypertension Research in the Twentieth Century. Amsterdam: Elsevier, 2004. p81-103.
55. Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 1998;31:64-67.
56. Greenwood JP, Stocker JB, Mary DASG. Single-unit sympathetic discharge. Quantitative assessment in human hypertensive disease. Circulation 1999;100: 1305-1310.
57. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108:560-565.
58. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010;298:R245-R253.
59. Krum H, Schlaich MP, Whitbourn R, Sobotka P, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
60. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic nerve ablation for the treatment of uncontrolled hypertension. N Engl J Med 2009;361: 932-934.
61. Esler M, Strasnicky N, Eikelis N, Masua K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006;48: 787-796.
62. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999;17:S29-S35.
63. Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.
64. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-882.
65. Parati G, Lombardi C, Narkiewicz K. Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk. Am J Physiol Regul Integr Comp Physiol 2007;293: R1671-R1683.
66. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HAJ, Zanchetti A. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
67. Cooper VL, Pearson SB, Bowker CM, Elliott MW, Hainsworth R. Interaction of chemoreceptor and baroreceptor reflexes by hypoxia and hypercapnia - A mechanism for promoting hypertension in obstructive sleep apnoea. J Physiol 2005;568: 677-687.
68. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897-1904.
69. Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 2003;26:15-19.
70. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995;8:222-229.
71. Watanabe T, Mano T, Iwase S, Sugiyama Y, Okada H, Takeuchi S, Furui H, Kobayashi F. Enhanced muscle sympathetic nerve activity during sleep apnea in the elderly. J Auton Nerv Syst 1992;37:223-226.
72. Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S, Weidmann P, Luscher TF. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996;93:866-869.
73. Ferrier C, Jennings GL, Eisenhofer G, Lambert G, Cox HS, Kalff V, Kelly M, Esler MD. Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension. J Hypertension 1993;11:1217-1227.
74. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apneahypopnea syndrome. Am J Respir Crit Care Med 2001;163:344-348.
75. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJO. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204-210.
76. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417-423.
77. Mohaupt MG, Schmidli J, Luft FC. Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension 2007;50:825-828.
78. Mancia G, Parati G, Zanchetti A. Electrical carotid baroreceptor stimulation in resistant hypertension. Hypertension 2010;55:607-609.
79. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FCGJ, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619-626.